The Petri Dish: Axcella advances long Covid drug

Flagship Pioneering spinout Axcella Therapeutics Inc. has promising results from a small Phase 2a study investigating a drug for long Covid.

Source: bizjournals.com Health Care:Physician Practices headlines - August 4, 2022 Category: American Health Authors: Rowan Walrath Source Type: news